Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients.

World journal of gastroenterology - 14 Dec 2013

Aprile Giuseppe, Lutrino Stefania Eufemia, Ferrari Laura, Casagrande Mariaelena, Bonotto Marta, Ongaro Elena, Puglisi Fabio

Abstract excerpt

Colorectal cancer (CRC) is a significant health problem, with around 1 million new cases and 500000 deaths every year worldwide. Over the last two decades, the use of novel therapies and more complex treatment strategies have contributed to progressively increase the median survival of patients with unresectable advanced CRC up to approximately 30 mo. The availability of additional therapeutic options, however,...

Topics

Join the communities discussing this publication.

Angiogenesis Inhibitors
Antineoplastic Combined Chemotherapy Protocols
Evidence-Based Medicine
Molecular Targeted Therapy
Patient Selection

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Precision Medicine

Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 24379565
DOI: 10.3748/wjg.v19.i46.8474
PMCID: PMC3870493

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients.PMID 24379565Read ↗

A perspective on emerging therapies in metastatic colorectal cancer: Focusing on molecular medicine and drug resistanceSemantic proximity Read ↗

Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015.Semantic proximity Read ↗

[Interpretation of the updates of NCCN 2017 version 1.0 guideline for colorectal cancer].Semantic proximity Read ↗

Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era.Semantic proximity Read ↗

Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019.Semantic proximity Read ↗

Metastatic colorectal cancer: current state and future directions.Semantic proximity Read ↗

First-Line Therapy in Metastatic, RAS Wild-Type, Left-Sided Colorectal Cancer: Should Everyone Receive Anti-EGFR Therapy?Semantic proximity Read ↗

Molecular Landscape and Therapeutic Strategies against Colorectal CancerSemantic proximity Read ↗

Personalizing medicine for metastatic colorectal cancer: current developments.Semantic proximity Read ↗

Clinical research progress on BRAF V600E-mutant advanced colorectal cancer.Semantic proximity Read ↗

Targeted Therapy in Metastatic Colorectal Cancer: Current Standards and Novel Agents in ReviewSemantic proximity Read ↗

Impact of biomarkers and primary tumor location on the metastatic colorectal cancer first-line treatment landscape in five European countries.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.